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Summary
Background: It has been reported that nitinol stents provide higher patency in
chronic phase than stainless steel stents after intervention to superﬁcial femoral
artery (SFA). However, there are few reports about stent patency for chronic total
occlusion of SFA (SFA CTO).
Objective: To compare clinical outcomes of self-expanding nitinol stents and stain-
less steel stents after percutaneous peripheral intervention (PPI) for SFA CTO.
Methods and results: Between April 2004 and August 2007, a total of 25 SFA CTO
lesions (nitinol stent group, 13; stainless steel stent group, 12) in 21 patients
were treated with PPI, all patients were followed clinically, and 21 lesions
(nitinol, 9; stainless steel, 12) received follow-up angiography. There was no sig-
niﬁcant difference in baseline characteristics, mean stent diameter (7.3± 0.7mm
vs. 6.9± 1.2mm, p = 0.32), pre-ankle-brachial index (ABI), and Fontaine stage
between groups. Mean occlusion length and stent length were signiﬁcantly longer
(129.5± 54.9mm vs. 39.0± 20.6mm, 250.8± 90.0mm vs. 145.2± 64.6mm, respec-
tively, p < 0.01) and number of stents was signiﬁcantly larger (2.8± 0.9 vs.
1.6± 0.5, p < 0.01) in the nitinol stent group. At follow-up, ABI was signiﬁcantly
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lower (0.73± 0.20 vs. 0.95± 0.13, p = 0.04), restenosis rate and target lesion revascu-
larization was signiﬁcantly higher (58.3% vs. 15.4%, p = 0.03; 50.0% vs. 7.7%, p = 0.02,
respectively) in the stainless steel stent group.
Conclusion: Our study demonstrates the superiority of nitinol stent implantation com-
pared with stainless steel stent implantation for SFA CTO.
e of Cardiology. Published by Elsevier Ireland Ltd. All rights
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the day after the procedure) was 0.95± 0.13 vs.
0.93± 0.09. There was no signiﬁcant difference
between groups (p = 0.70). But ABI at follow-up© 2009 Japanese Colleg
reserved.
Introduction
In the femoropopliteal artery segment, balloon
angioplasty is a recommended treatment strategy
for short lesions. Balloon-expanding stents are not
superior to balloon angioplasty for treatment of
short lesions, and self-expanding nitinol stents also
failed to show a beneﬁcial effect in short lesions
less than 5 cm [1]. However, over the past few
years, several reports have emerged on the poten-
tial role of self-expanding nitinol stents for treating
longer, more complex disease segments where the
patency following balloon angioplasty is notoriously
dismal [2]. Moreover, it has been reported that niti-
nol stents provide higher patency in chronic phase
than stainless steel stents after intervention to the
superﬁcial femoral artery (SFA). However, there are
few reports about stent patency for chronic total
occlusion (CTO) of the SFA. In this study, we com-
pared clinical outcomes of self-expanding nitinol
stents and stainless steel stents after percutaneous
peripheral intervention (PPI) for SFA CTO.
Methods
Enrolment began in April 2004 and ended in August
2007, at The Cardiovascular Institute Hospital. Dur-
ing this period, a total of 25 SFA CTO lesions
[nitinol stent (S.M.A.R.T Stent, Cordis Corp., Tokyo,
Japan) group, n = 13, stainless steel stent (Wall-
stent, Boston Scientiﬁc Corp., Watertown, MA, USA)
group, n = 12] in 21 patients were treated with
PPI. All patients received dual anti-platelet drugs
such as aspirin (81—100mg per day) and ticlopi-
dine (200mg per day) or cilostazol (200mg per day)
for at least 1 week before the procedure. Elective
stent implantation for SFA CTO was performed in
all cases. The choice of using a nitinol stent or a
stainless steel stent was left to the discretion of
the interventionist. During the procedure, heparin
was given as a bolus 5000U with additional boluses
to 1000U/h. After PPI, all patients were followed
clinically [including measurement of ankle-brachial
index (ABI), assessment of Fontaine staging in out-
p
u
h
(atient clinic] and 21 lesions (nitinol stent group, 9;
tainless steel stent group, 12) received follow-up
ngiography. Follow-up angiography was basically
erformed 6—12 months after procedure. But it was
erformed in the presence of symptoms suggest-
ng claudication and lowering of ABI at an unusual
ime. In our study, four lesions in four patients in
he nitinol stent group did not receive follow-up
ngiography because all of them refused it.
We examined the pre-/post-ABI, Fontaine stag-
ng, restenosis rate, and target lesion revascular-
zation (TLR) after PPI for SFA CTO.
tatistical analysis
tatistical analysis was performed using StatView-J
.0 (SAS institute, Cary, NC, USA). The Chi-square
est was used to evaluate categorical variables
i.e. occlusion length). Continuous variables were
xpressed ± standard deviation for each measure-
ent. Differences in continuous variables were
ssessed using the paired Student’s t-test (i.e. ABI
t follow-up period). A p-value <0.05 was consid-
red statistically signiﬁcant.
esults
aseline patient characteristics are shown in
able 1. There were no signiﬁcant differences
etween the two groups. Our procedure was suc-
essful in all cases.
Table 2 shows the comparison of nitinol stent and
tainless steel stent according to ABI and Fontaine
tage. Pre-ABI (measured on the previous day of
he procedure) was 0.56± 0.19 in the nitinol stent
roup, and 0.64± 0.09 in the stainless steel stent
roup. There was no signiﬁcant difference between
roups (p = 0.20). ABI just after PPI (measured oneriod was 0.92± 0.15 vs. 0.73± 0.20. At follow-
p, ABI in the nitinol stent group was signiﬁcantly
igher than that in the stainless steel stent group
p = 0.04).
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Table 1 Baseline patient characteristics.
Nitinol stent lesion (n = 13) Stainless steel stent lesion (n = 12) p-Value
Age, years 75.4± 6.3 70.4± 8.7 0.11
Male, n (%) 10 (76.9) 9 (75.0) 0.92
Hypertension, n (%) 12 (92.3) 10 (83.3) 0.51
Hyperlipidemia, n (%) 4 (30.8) 5 (41.7) 0.59
Diabetes mellitus, n (%) 7 (53.8) 8 (66.7) 0.53
Smoking, n (%) 9 (69.2) 4 (33.3) 0.08
Anti-platelet drugs, n (%)a 13 (100.0) 12 (100.0) 1.00
ACEI/ARB, n (%) 11 (84.6) 7 (58.3) 0.16
Statin, n (%) 6 (46.2) 5 (41.7) 0.83
Vasodilator drugs, n (%)b 9 (69.2) 10 (83.3) 0.43
Data are mean± S.D. of the number (%).
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II type 1 receptor blocker.
a More than two drugs (aspirin, ticlopidine, cilostazol, and so on).
b Isosorbide mononitrate, isosorbide dinitrate, calcium antagonist, and nicorandil were included.
Table 2 Comparison of nitinol stent and stainless steel stent according to ABI and Fontaine stage.
Nitinol stent lesion (n = 13) Stainless steel stent lesion (n = 12) p-Value
Pre-ABI 0.56 ± 0.19 0.64 ± 0.09 0.19
ABI just after PPI 0.95 ± 0.13 0.93 ± 0.09 0.70
ABI at follow-up 0.92 ± 0.15 0.73 ± 0.20 0.04
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4Pre-Fontaine stage 2.15 ± 0.56
Post-Fontaine stage at follow-up 0.69 ± 0.63
ABI, ankle-brachial index; PPI, percutaneous peripheral interv
Regarding the comparison of nitinol stent and
tainless steel stent according to Fontaine stage,
re-Fontaine stage (assessed from symptom up to
he point of pre-procedure) was 2.15± 0.56 in the
itinol stent group, and 1.92± 0.29 in the stainless
teel stent group. There was no signiﬁcant differ-
nce between groups (p = 0.20). But Fontaine stage
t follow-up (assessed from symptoms in chronic
hase) was 0.69± 0.63 vs. 1.42± 0.90. Follow-up
eriod Fontaine stage in the nitinol stent group was
igniﬁcantly lower than that in the stainless steel
tent group (p = 0.03).
Table 3 shows the comparison of both stent
roups according to lesion and stent characteris-
ics. Mean stent diameter was 7.3± 0.7mm in the
itinol stent group and 6.9± 1.2mm in the stain-
ess steel stent group. There was no signiﬁcant
ifference between groups (p = 0.32). Mean occlu-
ion length was 129.5± 54.9mm vs. 39.0± 20.6mm
g
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Table 3 Comparison of nitinol stent and stainless steel ste
Nitinol stent lesion (n = 13
Mean occlusion length (mm) 129.5 ± 54.9
Mean stent length (mm) 250.8 ± 90.0
Mean stent diameter (mm) 7.3 ± 0.7
Number of stents 2.8 ± 0.91.92 ± 0.29 0.20
1.42 ± 0.90 0.03
n.
nd mean stent length was 250.8± 90.0mm vs.
45.2± 64.6mm. In addition, the number of stents
as 2.8± 0.9 vs. 1.6± 0.5. Mean occlusion length
nd stent length were signiﬁcantly longer and num-
er of stents was signiﬁcant larger in the nitinol
tent group (p < 0.01, p < 0.01, p < 0.01, respec-
ively). Stainless steel stents were implanted in 12
esions, each of 5 (41.7%) lesions received 1 stent,
ach of 7 (58.3%) lesions received 2 stents. Niti-
ol stents were implanted in 13 lesions, each of 2
15.4%) lesions received 1 stent, each of 1 (7.7%)
esion received 2 stents, each of 8 (61.5%) lesions
eceived 3 stents, each of 2 (15.4%) lesions received
stents.
Table 4 shows the comparison of both stentroups according to clinical outcomes in chronic
hase. Mean follow-up period is 214± 125 days
n the nitinol stent group and 400± 352 days in
he stainless steel stent group (p = 0.08). Angio-
nt according to lesion and stent characteristics.
) Stainless steel stent lesion (n = 12) p-Value
39.0 ± 20.6 <0.01
145.2 ± 64.6 <0.01
6.9 ± 1.2 0.32
1.6 ± 0.5 <0.01
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Table 4 Comparison of nitinol stent and stainless steel stent according to clinical outcomes in chronic phase.
Nitinol stent Stainless steel stent p-Value
Follow-up period (days) 214± 125 400± 352 0.08
Follow-up angiography (lesions) 9 12
Angiographical restenosis (%) 2 (22.2) 7 (58.3) <0.01
TLR (%) 1 (11.1) 6 (50.0) <0.01
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lClinical driven TLR (%) 1 (7.7 = 1/13
Stent fracture (%) 0 (0)
TLR, target lesion revascularization.
graphical restenosis rate was 22.2% vs. 58.3%,
TLR was 11.1% vs. 50.0%, and clinical driven TLR
was 7.7% (1/13 lesions) vs. 50.0% (6/12 lesions).
Those were signiﬁcantly higher in the stainless steel
stent group (p < 0.01, p < 0.01, p = 0.02, respec-
tively). As to the four lesions that did not undergo
follow-up angiography, none of them had admitting
symptoms or lowering of ABI. So we determined
that they were making satisfactory progress clini-
cally.
In addition, there was no stent fracture case in
follow-up angiography.
Discussion
In the past, balloon angioplasty alone was the
treatment of choice for the femoropopliteal artery
segment. The TASC working group suggested that
primary success rates were above 90% with a very
low rate of complications (below 4%) [3]. But fail-
ure rates above 70% were observed at 1 year after
balloon angioplasty of lesions longer than 10 cm [4].
Recently, the application of self-expandable nitinol
stent technology seemed to improve the durability
of stenting in the femoropopliteal segment par-
ticularly to longer and more complex segments
[5—9]. Moreover, some studies have suggested that
chronically occluded SFAs could be treated by per-
cutaneous nitinol stenting techniques with a high
degree of success that was durable in the chronic
phase [10,11]. And it has been reported that nitinol
stents provide higher patency in the chronic phase
than stainless steel stents after intervention to SFA
‘‘stenotic’’ lesions [8].
The TASCII Working Group reported that with
regard to angiographical outcome in the chronic
phase after stenting for stenosis and occlusions
in femoropopliteal artery segments, 1 and 3 year
patency after stenting for SFA stenosis are 75% and
66% and for SFA occlusions are 73% and 64%. There is
almost no change in patency between SFA stenosis
and occlusions. In a word, if only a wire is crossed
to the SFA occlusion site, we can implant stents in
almost all cases and gain long patency using niti-
n
r
h
[ns) 6 (50.0 = 6/12 lesions) 0.02
0 (0) 1.00
ol stent that is superior to stainless steel stent.
ecent results evaluating stenting in TASC C and D
esions compare very favorably with contemporary
ata evaluating percutaneous transluminal angio-
lasty in TASC A lesions [12].
It was notable that clinical outcomes of inter-
ention to SFA ‘‘CTO’’ lesions comparing between
elf-expanding nitinol stents and stainless steel
tents were similar to that to SFA ‘‘stenotic’’
esions. To the best of our knowledge, the present
tudy is the initial report that could demonstrate
he superiority of nitinol stents implantation com-
ared with stainless steel stent implantation for
‘SFA CTO’’ only.
The 100% procedural success rate was depen-
ent on the use of the bi-directional (femoral and
opliteal) approach, with kissing catheter tech-
ique, to traverse from the occluded portion into
he reconstituted portion of the SFA [13]. In our
tudy, this technique was necessary in 14 lesions
nitinol stent group, 10/13; stainless steel stent
roup, 4/12) of the total 25 SFA CTO lesions.
Unique mechanical properties and reduced
hrombogenicity of the nitinol surface may con-
ribute to the reduction of instent neointimal
roliferation [14]. So we think that nitinol stents
rovide higher patency in the chronic phase than
tainless steel stents.
In the SFA segment, most investigators have
scribed the tendency to stent fracture to the
resence of multiple repetitive mechanical forces
xerted by the unique environment of the SFA such
s tortuous and ﬂexuous lesion [15,16]. Indeed
here are many cases of stent fracture in self-
xpandable nitinol and stainless steel stents, but
linical outcome is better in self-expandable nitinol
tents, so clinical deterioration seems to be no mat-
er of serious concern with self-expandable nitinol
tents [15].
In the coronary circulation, Kandzari and col-
eagues reported that the use of self-expanding
itinol stents had been shown to have promising
esults, even in vessels that were associated with
igh restenosis rates, such as saphenous vein grafts
17].
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[elf-expandable nitinol versus stainless steel stent
tudy limitations
irst, this study was performed in a small number of
atients. Second, in our study, stainless steel stent
roup patients were enrolled from April 2004 to
006, and nitinol stent group patients were enrolled
rom June 2006 to August 2007. So stainless steel
tents were used in the earlier phase, the mean
ollow-up periods and the standard deviations were
onsiderably different. In addition, our technique
hanged with times, we did not assess differences
f technical factors in both groups accurately.
onclusions
n conclusion, our study demonstrated the superi-
rity of nitinol stent implantation compared with
tainless steel stent implantation for SFA CTO. How-
ver, we believe randomized controlled trials are
eeded to conﬁrm these results because the effects
f confounding factors such as diabetes mellitus
annot be ruled out with certainty in a retrospec-
ive study.
eferences
[1] Schillinger M, Minar E. Endovascular stent implantation for
treatment of peripheral artery disease. Eur J Clin Invest
2007;37:165—70.
[2] Mewissen MW. Stenting in the femoropopliteal arterial seg-
ment. Tech Vasc Interv Radiol 2005;8:146—9.
[3] Dormandy JA, Ratherford B. Management of peripheral
artery disease (PAD) TASC Working Group TransAt-
lantic Inter-Society Consensus (TASC). J Vasc Surg
2000;31:S1—296.
[4] Capek P, McLean GK, Berkowitz HD. Femoropopliteal angio-
plasty. Factors inﬂuencing long-term success. Circulation
1991;83:I70—80.[5] Duda SH, Pusich B, Richter G, Landwehr P, Oliva VL, Tiel-
beek A, Wiesinger B, Hak JB, Tielemans H, Ziemer G, Cristea
E, Lansky A, Bérégi JP. Sirolimus-eluting stents for the
treatment of obstructive superﬁcial femoral artery disease:
six-month results. Circulation 2002;106:1505—9.
Available online at www.sA CTO 421
[6] Sabeti S, Mlekusch W, Amighi J, Minar E, Schillinger M.
Primary patency of long-segment self-expanding nitinol
stents in the femoropopliteal arteries. J Endovasc Ther
2005;12:6—12.
[7] Lugmayr HF, Holzer H, Kastner M, Riedelsberger H, Auterith
A. Treatment of complex arteriosclerotic lesions with niti-
nol stents in the superﬁcial femoral and popliteal arteries:
a midterm follow-up. Radiology 2002;222:37—43.
[8] Sabeti S, Schillinger M, Amighi J, Sherif C, Mlekusch W,
Ahmadi R, Minar E. Primary patency of femoropopliteal
arteries treated with nitinol versus stainless steel self-
expanding stents: propensity score-adjusted analysis.
Radiology 2004;232:515—21.
[9] Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Tiel-
beek A, Anderson J, Wiesinger B, Tepe G, Lansky A, Mudde
C, Tielemans H, Bérégi JP. Sirolimus-eluting versus bare
nitinol stent for obstructive superﬁcial femoral artery dis-
ease: the SIROCCOII trial. J Vasc Interv Radiol 2005;16:
331—8.
10] Dippel E, Shammas N, Takes V, Coyne L, Lemke J.
Twelve-month results of percutaneous endovascular recon-
struction for chronically occluded superﬁcial femoral
arteries: a quality-of-life assessment. J Invasive Cardiol
2006;18:316—21.
11] Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch
W, Schlager O, Cejna M, Lammer J, Minar E. Balloon angio-
plasty versus implantation of nitinol stents in the superﬁcial
femoral artery. N Engl J Med 2006;354:1879—88.
12] Dorrucci V. Treatment of superﬁcial femoral artery occlu-
sive disease. J Cardiovasc Surg 2004;45:193—201.
13] Conroy RM, Gordon IL, Tobis JM, Hiro T, Kasaoka S, Stemmer
EA, Wilson SE. Angioplasty and stent placement in chronic
occlusion of the superﬁcial femoral artery: technique and
results. J Vasc Interv Radiol 2000;11:1009—20.
14] Thierry B, Merhi Y, Bilodeau L, Trépanier C, Tabrizian
M. Nitinol versus stainless steel stents: acute thrombo-
genicity study in an ex vivo porcine model. Biomaterials
2002;23:2997—3005.
15] Schlager O, Dick P, Sabeti S, Amighi J, Mlekusch W, Minar E,
Schillinger M. Long-segment SFA stenting—–the dark sides:
in-stent restenosis, clinical deterioration, and stent frac-
tures. J Endovasc Ther 2005;12:676—84.
16] Smouse HB, Nikanorov A, LaFlash D. Biomechanical forces
in the femoropopliteal arterial segment. Endovasc Today
2005:60—6.
17] Kandzari DE, Goldberg S, Schwartz RS, Chazin-Caldie M,
Sketch Jr MH, SCORES SVG Registry Investigators. Clinical
and angiographic efﬁcacy of a self-expanding nitinol stent
in saphenous vein graft atherosclerotic disease: the Stent
Comparative Restenosis (SCORES) Saphenous Vein Graft
Registry. Am Heart J 2003;145:868—74.
ciencedirect.com
